Planegg-Martinsried, Germany, 18 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today published its Q1 2024 report, presenting all material developments up to 31 March 2024, as well as the Company’s current outlook. The full report is available for […]
Melanie Senior’s article in Nature Portfolio on ‘Precision Financing’ highlights the rigour behind private biotech financing in 2023 where strong data and efficiency are essential. Two of our clients, Naveed Siddiqi of Novo Holdings and Antoine Papiernik from Sofinnova Partners were featured. Here are some key takeaways… Since the pandemic, the biotech industry has experienced […]
Following Jeremy Hunt’s 2023 budget delivered earlier this month, in which he paved the way for faster access to new drugs and revealed R&D tax credits for life sciences companies, Bloomberg looked at the many challenges still facing the UK’s life sciences sector. Despite the success of the Oxford Covid-19 vaccine, the UK is still […]
Optimum is a proud supporter of LSX. Every year it’s World Congress gathers the founders and CEOs of innovative start-ups through to publicly healthcare giants, and everyone in between.
GENT, BELGIUM, April 5, 2022 – eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is pleased to announce the relocation of its R&D group to a new and larger site in Gent, Belgium. The upgraded R&D facility is in the Zwijnaarde Science Park, where a […]
